rebel Financial rebel Financial
← All Posts
XERS

XERIS BIOPHARMA HOLDINGS, INC.

June 05, 2026 • Author: Phil Ratcliff • XERS
Item Proposal Vote
1 To elect two Class II directors to our board of directors to serve until the 2029 Annual Meeting of Stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal;
1.1 Dawn Halkuff ✓ For
1.2 John Johnson ✓ For
2 To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026; ✓ For
3 To approve, on a non-binding advisory basis, the compensation of our named executive officers; ✓ For
Attachments
📄
XERS_2026_Proxy_Statement.pdf 2.8 MB
📄
XERS_2025_Annual_Report.pdf 2.9 MB
This article was written for information purposes only and its content should not be construed by any consumer and/or prospective client as rebel Financial's solicitation to affect, or attempt to affect transactions in securities, or the rendering of personalized investment advice for compensation. No client or prospective client should assume that any such discussion serves as the receipt of, or a substitute for, personalized advice from rebel Financial, or from any other investment professional. See our disclosures page for more information.